MCMary Anti Chama

Mary Anti Chama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mary Anti Chama has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Beverly Egyir

    Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana

    3 shared publications
  • Dorcas Osei-Safo

    Department of Chemistry, School of Physical and Mathematical Sciences, College of Basic and Applied Sciences, University of Ghana, Legon, Accra P.O. Box LG 56, Ghana

    3 shared publications
  • Andreas Bender

    Yusuf Hamied Department of Chemistry, University of Cambridge, United Kingdom

    2 shared publications
  • Dorcas Osei-Safo

    Department of Chemistry, SPMS, CBAS, University of Ghana, Ghana

    2 shared publications
  • Ivan Addae-Mensah

    Department of Chemistry, School of Physical and Mathematical Sciences, P.O Box LG 56, University of Ghana, Legon, Ghana

    2 shared publications
  • Jessica Asomaniwaa Armah

    Department of Chemistry, School of Physical and Mathematical Sciences, University of Ghana, Legon, Accra, Ghana

    2 shared publications

Latest Publications

  • Open Access

    Computational applications in secondary metabolite discovery (CAiSMD) 2026: focus on secondary metabolites towards drug discovery

    by Fidele Ntie-Kang, Jude Y. Betow, Donatus B. Eni, Jonathan A. Metuge, Albisto Adriano, Mary Anti Chama, Hans Denis Bamal, Philippe Belle Ebanda Kedi, Lívia Mendes Campos, Abubakar Sadiq Abdullahi, et al.

  • Open Access

    Therapeutic Potential of Dichapetalin M in Metastatic and ER-positive Breast Cancer: Evidence from Cell Line Studies

    by George Yankson, Kezia Yaa Awortwe, Mary Anti Chama, Lily Paemka

    Background: Dichapetalin M (Dic M), an active compound extracted from medicinal plants in the Dichapetalum genus, has been previously shown to possess anti-proliferative activity against cancer cell lines. However, the specific mechanism through which it exerts its anticancer effects remains unknown. Purpose: This study focused on elucidating the mechanism of action of dichapetalin M to further explore its potential as a therapeutic agent for resistant and metastatic breast cancer. Method: We confirmed the Estrogen Receptor (ER) as a target of Dic M, using an in vitro approach. Furthermore, we examined both the apoptotic and migrastatic effects of dichapetalin M by assessing its impact on the expression of key apoptosis-related and cancer cell migration genes. Finally, we evaluated the compound’s effect on Multi-drug Resistance Gene MDR1 expression, a gene linked to cancer drug resistance. Results: Our target validation experiments demonstrated that Dic M exhibited considerably higher cytotoxicity in ER-positive breast cell lines compared to ER-negative cell lines. Furthermore, treatment of MCF-7 cells (which are ER-positive) with Dic M led to a dose-dependent increase in the expression of AREG (amphiregulin) , a downstream effector of the Estrogen Receptor. Additionally, Dic M inhibited actin polymerization and significantly downregulated genes involved in the turnover of actin monomers. Scratch-wound assay results further demonstrate that Dic M reduces the rate of cell migration, although its impact on EMT-related gene expression was only observed at high doses. Additionally, Dic M treatment in MCF-7 cells resulted in a significant decrease in the expression of pro-apoptotic genes and MDR1 expression. Conclusions: These findings indicate that Dic M likely interacts with the Estrogen Receptor and employs the apoptotic pathway to exert its cytotoxic and anti-proliferative effects. Dic M exhibits promising potential, such as anti-migrastatic properties and downregulation of a key breast cancer resistance gene, warranting further investigation.

  • Open Access

    In vitro Antiparasitic and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Activities of Extracts and Fractions from Pouteria alnifolia

    by Mary Anti Chama, Jessica Asomaniwaa Armah, Nadia Alhassan, Gabriella Ama Amoakoma Essuman, Julius King Kwame Tuekpe, Zenabu Lansah Alidu, Amina Bukari, Fauzia Nurudeen, Ian Tietjen, Theresa Manful Gwira

    Background: Although there is widespread use of herbal medicine in many parts of the world including tropical Africa, scientific evidence to validate efficacy and safety is largely scarce. The aim of this study was to investigate the potential of Pouteria alnifolia as an alternative anti-infective. Methods: In this study, bioactivity-guided isolation of extracts from different parts of P. alnifolia was done, and the in vitro antitrypanosomal, antileishmanial, anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cytotoxicity properties of the extracts and fractions were determined using the alamarBlue assay. Using microscopy, the growth kinetics of Trypanosoma brucei brucei was investigated by counting cells when parasites were exposed to different concentrations of selected extracts and fractions. Results: The results show that while anthracene and anthraquinone derivatives were absent in all the tested fractions, terpenoids, and cardiac glycosides were the most common phytochemicals in the fractions. Alkaloids were also detected in the dichloromethane (DCM) extracts of seeds and whole fruit (WF) compared to butanol (BuOH) fractions of the fruit pulp, stem, and roots. The IC 50 values for T. b. brucei were between 07 ± 0.0 and 59.5 ± 0.3 µg/mL while that of Leishmania donovani ranged from 1.3 ± 0.1 to 27.8 ± 1.8 µg/mL. DCM extracts from WF, seeds, and stem inhibited the growth of T. b. brucei , whereas the BuOH fractions from seeds and WFs were most active against SARS-CoV-2. Conclusion: Extracts and fractions from P. alnifolia appear to have useful chemotherapeutic agents that warrant further study for a variety of infections faced by those in tropical Africa.

  • The dichapetalins and dichapetalin-type compounds: structural diversity, bioactivity, and future research perspectives

    by Ivan Addae-Mensah, Godwin Akpeko Dziwornu, Mary Anti Chama, Dorcas Osei-Safo

    This review discusses the structural diversity of the dichapetalins and related compounds from the genera Dichapetalum and Phyllanthus, their manifestation in the diversity of their biological activities, and areas of potential future research.


  • Open Access

    Evaluation of the Antitrypanosomal Activity of the Crude Extracts of Uvaria Ovata: In vitro and In silico Approach

    by Mary Anti Chama, Beverly Egyir, Kofi Baffour-Awuah Owusu, Jessica Asomaniwaa Armah, Michael Afiadenyo, Samuel Kojo Kwofie

    Background: Human African trypanosomiasis is the third disease with most mortalities among the neglected tropical diseases. The absence of vaccines and the development of parasite resistance have necessitated the quest for new affordable and safe treatment options for the disease. This study aims to assess the potential ofUvaria ovataas an alternative new and safer antitrypanosomal therapeutics.Methods: Antitrypanosomal efficacies of extracts and fractions ofU. ovatawere determined by the Alamar Blue cell viability assay againstTrypanosoma brucei bruceiGUTat 3.1. Molecular docking was used to suggest the mechanism of action of the extracts and fractions by docking the curated compounds present in the plant against farnesyl diphosphate synthase (FPPS) and ornithine decarboxylase (ODC) enzymes.Results: Antitrypanosomal activities (IC50, μg/mL) obtained were within the range of 0.12–4.40, exceeding that of the standard suramin (4.96). A total of 17 known compounds fromU. ovatathat did not violate Lipinski’s rule of five with negligible toxicity produced molecular docking results against FPPS and ODC enzymes. Within the FPPS interaction landscape, mannosamine emerged as the most promising lead, with a binding energy of −6.4 kcal/mol and a predicted Ki value of 20.12 μM. With respect to ODC, 15 compounds exhibited binding affinities ranging from −4.6 to −6.3 kcal/mol, exceeding that of the known inhibitor allicin (−4.5 kcal/mol).Conclusion: This is the first report of the antitrypanosomal activity and mode of action suggestion ofU. ovata. The study sets the foundation for further exploration and validation of the therapeutic prospect ofU. ovatain the fight against trypanosomiasis.


  • Open Access

    Antimicrobial and in silico studies of the triterpenoids of Dichapetalum albidum

    by Mary A. Chama, Godwin A. Dziwornu, Elizabeth Popli, Eduard Mas-Claret, Beverly Egyir, Daniel M. Ayine-Tora, Kofi B-A. Owusu, David G. Reid, Dorcas Osei-Safo, Melinda Duer, et al.


  • Open Access

    Antiproliferative Activities of Methanolic Extract and Fractions of Tetrapleura Tetraptera Fruit

    by Anastasia Rosebud Aikins, Peggy Afua Birikorang, Mary Chama, Eunice Dotse, Abigail Anning, Regina Appiah-Opong

    Most of the current cancer chemotherapeutics are associated with harsh and undesirable side effects, including toxicity and chemoresistance, driving the need for safer and more effective alternatives. In this study, the antiproliferative activities of the methanolic extract of Tetrapleura tetraptera fruits and nine different fractions (C1C9) from the column chromatographic separation of the extract against leukemia (Jurkat) and human breast cancer (MCF-7) cell lines were investigated using a tetrazolium-based colorimetric assay. Phytochemical screening of the extract and fractions found alkaloids, carbohydrates, flavonoids, glycosides, phenols, saponins, steroids, tannins, and terpenoids in the methanolic extract. Most of the fractions exhibited antiproliferative activity (>100μg/mL) with the Jurkat cells being more susceptible than the MCF-7 cells. Four of the collected fractions C4, C3, C5, and C2 had good selective indices in decreasing order of activity, in the case of Jurkat cells. Liquid chromatography-mass spectrometry analysis of all samples (except for C4 and C9) revealed that C1, C2, C3, and C5 each had a single component. More importantly, fractions C2, C3, and C5, which were selective to Jurkat cells, also had the same retention time of 1.846min. Fractions C6 and C8 had two components, with C7 having four components. This study serves as a basis for further work to isolate and characterize potential anticancer agents from the fractions of extracts of T. tetraptera fruits.


  • Towards understanding antimicrobial activity, cytotoxicity and the mode of action of dichapetalins A and M using in silico and in vitro studies

    by Mary Anti Chama, Dezso Modos, Lewis Howard Mervin, Kofi Baffour-Awuah Owusu, Daniel Moscoh Ayine-Tora, Beverly Egyir, Lily Paemka, George Yankson, Mitsuko Ohashi, Avid Muammar Afzal, et al.


  • Open Access

    In vitro activities of crude extracts and triterpenoid constituents of Dichapetalum crassifolium Chodat against clinical isolates of Schistosoma haematobium

    by Mary Anti Chama, Henry Akwaffo Onyame, Claudine Fleischer, Dorcas Osei-Safo, Reiner Waibel, Joseph Otchere, Ivan Addae-Mensah, Michael Wilson


  • Open Access

    Constituents of the Roots of Dichapetalum pallidum and Their Anti-Proliferative Activity

    by Dorcas Osei-Safo, Godwin Akpeko Dziwornu, Regina Appiah-Opong, Mary Anti Chama, Isaac Tuffour, Reiner Waibel, Richard Amewu, Ivan Addae-Mensah

    As part of our search for bioactive compounds from the Dichapetalaceae, repeated chromatographic purification of the roots of a hitherto unexamined species, Dichapetalum pallidum, led to the isolation of the newly occurring 7-hydroxydichapetalin P (1) and the known dichapetalins A (2) and X (3). Also isolated were the known compounds friedelin-2,3-lactone (4), friedelan-3-one (6), friedelan-3β-ol (7) and pomolic (8), as well as the dipeptide aurantiamide acetate (5). The compounds were characterized by direct interpretation of their IR, 1D NMR and 2D NMR spectral data and by comparison of their physico-chemical data, including their chromatographic profiles, with the literature and authentic samples in our compound library for the genus Dichapetalum. The compounds were assayed for their anti-proliferative activities against the human T-lymphocytic leukemia (Jurkat), acute promyelocytic leukemia (HL-60) and T-lymphoblast-like leukemia (CEM) cell lines. Overall, dichapetalin X showed the strongest (3.14 μM) and broadest cytotoxic activities against all the leukemic cell lines tested, exhibiting even stronger activities than the standard compound, curcumin.